Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (12)
  • Open Access

    ARTICLE

    Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

    JINXIA CHEN1,2,3,#, SULI DAI1,2,#, GENG ZHANG4,5, SISI WEI1,2, XUETAO ZHAO3, YANG ZHENG1,2, YAOJIE WANG1,2, XIAOHAN WANG1,2, YUNJIANG LIU4,5,*, LIANMEI ZHAO1,2,*

    Oncology Research, Vol.32, No.11, pp. 1791-1802, 2024, DOI:10.32604/or.2024.049348 - 16 October 2024

    Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC.… More > Graphic Abstract

    Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation <i>in vitro</i>

  • Open Access

    ARTICLE

    ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling

    XIA DA1, HAN GE2, JUNFENG SHI3, CHUNHUA ZHU1, GUOZHU WANG1, YUAN FANG4,*, JIN XU1,*

    Oncology Research, Vol.32, No.7, pp. 1209-1219, 2024, DOI:10.32604/or.2024.045433 - 20 June 2024

    Abstract Objective: This study aimed to investigate the role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in triple-negative breast cancer (TNBC). Methods: ROR2 expression in primary TNBC and metastatic TNBC tissues was analyzed by immunohistochemical staining and PCR. ROR2 expression in TNBC cell lines was detected by PCR and Western blot analysis. The migration, invasion and chemosensitivity of TNBC cells with overexpression or knockdown of ROR2 were examined. Results: ROR2 expression was high in metastatic TNBC tissues. ROR2 knockdown suppressed the migration, invasion and chemoresistance of TNBC cells. ROR2 overexpression in MDA-MB-435 cells promoted the migration, More >

  • Open Access

    ARTICLE

    Identification of an immune classifier for predicting the prognosis and therapeutic response in triple-negative breast cancer

    KUAILU LIN1,2, QIANYU GU2, XIXI LAI2,3,*

    BIOCELL, Vol.47, No.12, pp. 2681-2696, 2023, DOI:10.32604/biocell.2023.043298 - 27 December 2023

    Abstract Objectives: Triple-negative breast cancer (TNBC) poses a significant challenge due to the lack of reliable prognostic gene signatures and an understanding of its immune behavior. Methods: We analyzed clinical information and mRNA expression data from 162 TNBC patients in TCGA-BRCA and 320 patients in METABRIC-BRCA. Utilizing weighted gene coexpression network analysis, we pinpointed 34 TNBC immune genes linked to survival. The least absolute shrinkage and selection operator Cox regression method identified key TNBC immune candidates for prognosis prediction. We calculated chemotherapy sensitivity scores using the “pRRophetic” package in R software and assessed immunotherapy response using the… More >

  • Open Access

    ARTICLE

    A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells

    EUN SOOK KIM1, SANGHEE KIM2, AREE MOON1,*

    Oncology Research, Vol.31, No.6, pp. 867-875, 2023, DOI:10.32604/or.2023.030411 - 15 September 2023

    Abstract Invasion and metastasis are important hallmarks of breast cancer and are the leading cause of patient mortality. Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by a poor prognosis and a lack of effective targeted therapies. The present study investigated the inhibitory effect of a novel FTY720 derivative on the invasive phenotype of TNBC cells. Here, we showed that a novel compound with an isoxazole ring, 4-(3-Decylisoxazol-5-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-aminium chloride (CM2-II-173), significantly inhibited invasiveness of MDA-MB-231 TNBC cells. Expression of matrix metalloproteinase (MMP)-9 and invasiveness of MCF10A normal breast cells induced by sphingosine-1-phosphate… More >

  • Open Access

    REVIEW

    Targeting triple-negative breast cancer: A clinical perspective

    LAZAR S. POPOVIC1,2,*, GORANA MATOVINA-BRKO1, MAJA POPOVIC1,2, KEVIN PUNIE3, ANA CVETANOVIC4,5, MATTEO LAMBERTINI6,7

    Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525 - 22 May 2023

    Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of… More > Graphic Abstract

    Targeting triple-negative breast cancer: A clinical perspective

  • Open Access

    ARTICLE

    The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway

    SHUIZHONG CEN1,#, XIAOJIE PENG2,#, JIANWEN DENG3,#, HAIYUN JIN4, ZHINAN DENG5, XIAOHUA LIN3, DI ZHU3, MING JIN6, YANWEN ZHU3, PUSHENG ZHANG3, YUNFENG LUO3, HONGYAN HUANG3,*

    Oncology Research, Vol.31, No.3, pp. 375-388, 2023, DOI:10.32604/or.2023.028256 - 22 May 2023

    Abstract Triple-negative breast cancer (TNBC) is characterized by fast growth, high metastasis, high invasion, and a lack of therapeutic targets. Mitosis and metastasis of TNBC cells are two important biological behaviors in TNBC malignant progression. It is well known that the long noncoding RNA AFAP1-AS1 plays a crucial role in various tumors, but whether AFAP1-AS1 is involved in the mitosis of TNBC cells remains unknown. In this study, we investigated the functional mechanism of AFAP1-AS1 in targeting Polo-like Kinase 1 (PLK1) activation and participating in mitosis of TNBC cells. We detected the expression of AFAP1-AS1 in the TNBC… More > Graphic Abstract

    The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway

  • Open Access

    ARTICLE

    G-Protein-Coupled Estrogen Receptor Enhances the Stemness of Triple-Negative Breast Cancer Cells and Promotes Malignant Characteristics

    Dongliang Zhu1,*, Jun Yang2, Jiaxin Xu3

    Oncologie, Vol.24, No.3, pp. 471-482, 2022, DOI:10.32604/oncologie.2022.024062 - 19 September 2022

    Abstract G-protein coupled estrogen receptor (GPER) is a transmembrane receptor that mediates non-genomic effects of estrogen. This study aimed to investigate the role of GPER in the stemness formation and malignancies in triple negative breast cancer (TNBC) cells. Spheroids of MDA-MB-468 cells were induced by mammosphere culture, and the proportion of the CD44+ /CD24−/low stem cell subpopulation was detected. Malignant characteristics, expression of GPER and stemness-related markers, and tumorigenesis in a xenograft assay were compared between the mammospheres and adherent cultured cells. The impacts of 17β-estradiol (E2) and the GPER-specific antagonist G15 were studied in in vitro assays.… More >

  • Open Access

    ARTICLE

    Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation

    POOJA JAISWAL1, VERSHA TRIPATHI1, ANSHUL ASSAIYA2, DHARMENDRA KASHYAP3, RAHUL DUBEY4, ANAMIKA SINGH4, JANESH KUMAR2, HEM CHANDRA JHA3, RAJESH SHARMA5, AMIT KUMAR DIXIT6, HAMENDRA SINGH PARMAR1,*

    BIOCELL, Vol.46, No.12, pp. 2645-2657, 2022, DOI:10.32604/biocell.2022.021754 - 10 August 2022

    Abstract Triple-negative breast cancer (TNBC) cell line MDA-MB-231 is known for Warburg metabolism and defects in mitochondria. On the other hand, dipeptidyl peptidase-IV (DPP-IV) inhibitors such as sitagliptin and vildagliptin and GLP-1 agonist exendin-4 are known to improve mitochondrial functions as well as biogenesis, but no study has evaluated the influence of these drugs on mitochondrial biogenesis on metastatic breast cancer cell line. We have recently reported anticancer effects of 5-aminoimidazole-4-carboxamide riboside on MDA-MB-231 cells via activation of AMP-dependent kinase (AMPK), which activates the downstream transcription factors PGC-1α, PGC-1β, or FOXO1 for mitochondrial biogenesis; above-mentioned incretin-based… More >

  • Open Access

    REVIEW

    Identification of a three-gene signature in the triple-negative breast cancer

    LIPING WANG1,2, ZHOU LUO1, MINMIN SUN3, QIUYUE YUAN4, YINGGANG ZOU5, DEYUAN FU1,*

    BIOCELL, Vol.46, No.3, pp. 595-606, 2022, DOI:10.32604/biocell.2022.017337 - 18 November 2021

    Abstract This work aimed to improve current prognostic signatures based on clinical stages in identifying high-risk patients of triple-negative breast cancer (TNBC), to allow patients with a high-risk score for specific treatment decisions. In this study, 396 TNBC samples from TCGA and GEO databases were included in genome-wide transcriptome analysis. The relationship between normalized gene expression values and survival data of patients was determined by Cox proportional hazards models in each dataset. The overlapped genes among all datasets were considered as a potential prognostic signature. The risk score was constructed based on individual genes and validated… More >

  • Open Access

    ARTICLE

    Hypoxia-associated circular RNA RPPH1 modulates triple-negative breast cancer cell growth via the miR-1296-5p/TRIM14 axis

    DILIXIATI JINSIHAN, DAN LI, MINGSHUAI ZHANG, JINCHUN FENG, QIAN ZHAO*

    BIOCELL, Vol.45, No.3, pp. 671-684, 2021, DOI:10.32604/biocell.2021.012519 - 03 March 2021

    Abstract Hypoxia affects the advancement, metastasis, and metabolism of breast cancer (BC). The circular RNA ribonuclease P RNA component H1 (circRPPH1) (has_circ_0000515) is implicated in tumor progression. Nevertheless, the regulatory mechanism related to circRPPH1 in hypoxia-mediated triple-negative breast cancer (TNBC) progression is indistinct. The expression levels of circRPPH1, miR-1296-5p, tripartite motif-containing 14 (TRIM14) mRNA in tissue samples and cells were examined through quantitative real-time polymerase chain reaction (qRT-PCR). Cell viability, migration, and invasion were determined with Cell Counting Kit-8 (CCK-8) or transwell assays. The levels of glucose consumption and lactate production were assessed via the Glucose… More >

Displaying 1-10 on page 1 of 12. Per Page